Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392.
[2]
Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767-778.
[3]
Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(4):465-482.
[4]
Giancane G, Consolaro A, Lanni S, Davì S, Schiappapietra B, Ravelli A. Juvenile Idiopathic Arthritis: Diagnosis and Treatment. Rheumatol Ther. 2016;3(2):187-207.
[5]
Culliford D, Maskell J, Kiran A, et al. The lifetime risk of adult-onset rheumatoid arthritis, rheumatoid arthritis-related hospitalisation and mortality. Rheumatology (Oxford). 2012;51(6):1159-1160.
[6]
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-2149.
[7]
Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717-734.
[8]
Grom AA, Mellins ED. Macrophage activation syndrome: advances in understanding etiology and pathogenesis. Clin Immunol. 2010;137(1):10-19.
[9]
Heiligenhaus A, Heinrich C, Stingl J, et al. Improvement of screening for uveitis in juvenile idiopathic arthritis. Klin Monbl Augenheilkd. 2004;221(10):809-815.
[10]
Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with polyarticular juvenile idiopathic arthritis treated with systematic DMARD initiation: results of a two-year longitudinal study. Arthritis Rheum. 2007;56(12):3987-3998.